A cell culture (Vero)-derived H5N1 whole-virus vaccine induces cross-reactive memory responses

Journal of Infectious Diseases

Volumn 200, Issue 7, 2009, Pages 1113-1118

  Ehrlich, Hartmut J ^a   Müller, Markus ^b   Fritsch, Sandor ^a   Zeitlinger, Markus ^b   Berezuk, Greg ^a   Löw Baselli, Alexandra ^a   Van Der Velden, Maikel V W ^a   Pöllabauer, Eva Maria ^a   Maritsch, Friedrich ^a   Pavlova, Borislava G ^a   Tambyah, Paul A ^c   Oh, Helen M L ^d   Montomoli, Emanuele ^e   Kistner, Otfried ^a   Noel Barrett, P ^a  

^a BAXTER BIOSCIENCE   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d CHANGI GENERAL HOSPITAL   (Singapore)

^e UNIVERSITY OF SIENA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE;

ARTICLE; CELL CULTURE; CLINICAL TRIAL; CROSS REACTION; DRUG INDUCED HEADACHE; DRUG SAFETY; HUMAN; IMMUNOGENICITY; INFLUENZA VIRUS A H5N1; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE REACTION; INJECTION SITE SWELLING; MAJOR CLINICAL STUDY; MALAISE; PRIORITY JOURNAL;

ANIMALS; ANTIBODIES, VIRAL; CERCOPITHECUS AETHIOPS; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; HUMANS; IMMUNIZATION, SECONDARY; IMMUNOLOGIC MEMORY; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; VERO CELLS;

EID: 70349326545     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/605608     Document Type: Article

References (15)

1. WHO. Cumulative number of confirmed human, cases of avian influenza A/(H5N1) reported to WHO. 17 April 2009. Available at; http;// www.who.int/csr/disease/avian-influ.enza/country/cases-table-2009 -04-17/en/index.html. Accessed 20 April 2009.
2. WHO. Antigenic and genetic characteristics of H5N1 viruses and candidate H5N1 vaccine viruses developed for potential use as pre-pandemic vaccines. February 2009. Available at; http://www.who.int/csr/ disease/avian-influenza/ guidelines/h5nlvirus/en/index.html. Accessed 20 April 2009.
3. Nguyen. TD, Nguyen TV, Vijaykrishna D, et al. Multiple sublineages of influenza A virus (H5N1), Vietnam, 2005-2007. Emerg Infect Dis 2008;14:632-636
4. Ehrlich HJ, Mueller M, Oh HML, et al. A clinical trial of a wholevirus H5N1 vaccine derived from cell culture. N Engl J Med 2008; 358:2573-2584
5. Schild GC, Pereira MS, Chakraverty P. Single-radial-hemolysis: a new method for the assay of antibody to influenza haemagglutinin. Bull World Health Organ 1975;52:43-50.
6. Ferguson NM, Cummings DAT, Fraser C, Cajka JC, Cooley PC, Burke DS. Strategies for mitigation an influenza pandemic. Nature 2006; 442: 448-452
7. Leroux-Roels I, Borkowsky A, Vanwolleghem T, et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5Nl prototype pandemic influenza vaccine: a randomized controlled trial. Lancet 2007; 370:580-589 (Pubitemid 47247854)
8. Leroux-Roels I, Bernhard R, Gérard P, Drame M, Hanon E, LerouxRoels G. Broad clade 2 cross-reactive immunity induced by an adjuvanted clade 1 rH5Nl pandemic influenza vaccine. PloS ONE 2008; 3:e1665. (Pubitemid 351865662)
9. Nicholson KG, Colegate AE, Podda A, et al. Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/ 97 (H5N3) vaccine: a randomized trial of two potential vaccines against H5N1 influenza. Lancet 2001;357:1937-1943.
10. Stephenson I, Nicholson KG, Colegate A, et al. Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population. Vaccine 2003;21:1687-1693 (Pubitemid 36287599)
11. Stephenson I, Bugarini R, Nicholson KG, et al. Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/ 97 (H5N3) vaccine: a potential priming strategy. J Infect Dis 2005; 191:1210-1215 (Pubitemid 40503646)
12. Nicholson KG, Tyrrell DAJ, Harrison P, et al. Clinical studies of monovalent inactivated whole virus and subunit A/USSR/77 (H1N1) vaccine: serological responses and clinical reactions. J Biol Stand 1979; 7:123-136 (Pubitemid 9149059)
13. Stephenson I, Nicholson KG, Hoschler K, et al. Antigenically distinct MF59-adjuvanted vaccine to boost immunity to H5N1. N Engl J Med 2008;359:1631-1633
14. Zangwill KM, Treanor JJ, Campbell JD, Noa DL, Ryea J. Evaluation of the safety and immunogenictiy of a booster (third) dose of inactivated subvirion H5N1 influenza vaccine in humans. J Infect Dis 2008; 197: 580-583 (Pubitemid 351321536)
15. Goji N, Nolan C, Hill H, et al. immune response of healthy subjects to a single dose of intramuscular inactivated influenza A/Vietnam/1203/ 2004 (H5N1) vaccine after priming with an antigenic variant. J Infect Dis 2008; 198:635-641